Skip to main content

Protocol of CLOuD of published in the BMJ

A research protocol for a randomised parallel study assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy has been published in the British Medical Journal, on behalf of the CLOuD Consortium.


Prof R Hovorka
Professor Roman Hovorka

Professor of Metabolic Technology, University of Cambridge

The CLOuD study builds on recent technological advances of closed-loop insulin delivery (artificial pancreas). The purpose of this study is to test the impact of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion.

The primary objective is to evaluate the effect of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion by comparing the area under the stimulated C-peptide curve (AUC) of a mixed meal glucose tolerance test conducted at the 12-month visit in participants receiving closed-loop insulin delivery with those receiving standard therapy, i.e. multiple daily injections applying basal-bolus regimen.

Published April 22, 2020

Latest from CCTU

Improving outcomes for Crohn's patients

Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.

Roll out of Cambridge-developed artificial pancreas is world first

An artificial pancreas developed with the help of staff and patients at Addenbrooke's Hospital is one of four new devices to be rolled out by…

New clues about irritable bowel syndrome found in the brain

Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.

All news